Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.
Let’s take a stroll down memory lane...
AUGUST, 2018
Sequence Bio’s NB Genome Project - Pilot receives approval from Veritas, a nationally recognized ethics review board of Canadian genomics and ethics experts.
MAY, 2018
Newfoundland and Labrador’s Research Ethics Board announces the creation of a subcommittee specific to genetic / genomics research.
JANUARY, 2018
Genomics expert Dr. Michael S. Phillips joins the Sequence team as Chief Scientific Officer.
DECEMBER, 2017
Sequence Bio wins Community Impact and Business Excellence awards at the St. John's Board of Trade Awards.
NOVEMBER, 2017
Sequence Bio CEO, Chris Gardner, appointed to the newly created federal Health/Bio-sciences Economic Strategy Table by the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development.
SEPTEMBER, 2017
Dr. Kathy Hudson is named Chair of our Scientific Advisory Board.
MAY, 2017
Bill S201 is passed in Canada, ensuring protection from genetic discrimination. Sequence Bio worked with former Senator Jim Cowan to support this important piece of legislation.
MARCH, 2017
Sequence Bio reaches 20 employees (plus one loveable pup)!
FEBRUARY, 2017
The Sequence team moves into a new and expanded office space in St. John’s, Newfoundland & Labrador (on the oldest street in North America in fact!).
DECEMBER, 2016
Dr. Gerry Mugford joins Sequence Bio as Director of Research. Dr. Mugford is Director of Clinical Epidemiology and an Associate Professor of Medicine and Psychiatry at Memorial University.
AWSis launched in Canada and Sequence Bio is a featured client!
OCTOBER, 2016
Chris Gardner, CEO & President, and Karen Moores, VP Public Affairs, head to Ottawa to advocate on behalf of Bill S-201 with Honourable Senator Jim Cowan to prevent genetic discrimination.
SEPTEMBER, 2016
Stanford’s Dr. Euan Ashley joins our Scientific Advisory Board and James Hardiman from DCVC joins our Board of Directors - both bringing unmatched expertise to the team.
AUGUST, 2016
$3 million USD seed financing led byDCVCis raised by Sequence Bio, the first Silicon Valley financing of this kind in Atlantic Canada.
Sequence Bio attends the New England Governors - Atlantic Canadian Premiers Summit in Boston, MA.
JULY, 2016
DNA Genotekand Sequence Bio enter into a supply agreement for custom DNA collection kits to use in the future.
JUNE, 2016
Mark Dobbin and Dr. Andrew Furey join our Board of Directors to offer their guidance to help achieve our goal of enabling better healthcare across Newfoundland and Labrador.
APRIL, 2016
Master licensing agreement with Memorial University is signed to help advance drug discovery research.
OCTOBER, 2015
Sequence Bio and the Government of Newfoundland and Labrador sign a MOU to launch a large-scale precision medicine initiative in the future.
Dr. Pek Lum of Capella Bioscience joins the Sequence Bio Scientific Advisory Board.
SEPTEMBER, 2015
$1,000,000 Seed Round of Financing closes, led by Killick Capital, Pelorus Venture and Klister Capital Corp.
AUGUST, 2014
Sequence Bio completes the Canadian Trade Accelerator program at the Cambridge Innovation Centre in Boston, MA.
